Shareholders of Merck & Co., Inc. Should Contact The Gross Law Firm Before April 14, 2025 to Discuss Your Rights – MRK

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Merck & Co., Inc. regarding a class action lawsuit related to misleading statements about the company's expected revenue from Gardasil sales by 2030 [1][3]. Summary by Relevant Sections Allegations - The complaint alleges that Merck's management provided investors with optimistic forecasts, claiming expected revenue of $11 billion from Gardasil sales by 2030, driven by successful consumer activation and education efforts [3]. - The truth emerged on February 4, 2025, when Merck announced it would not achieve the projected $11 billion in sales, ceasing shipments of Gardasil to China to reduce inventory due to lower-than-expected demand [3]. - Following this announcement, Merck's stock price fell from $99.79 per share on February 3, 2025, to $90.74 per share on February 4, 2025, marking a decline of over 9% in one day [3]. Next Steps for Shareholders - Shareholders who purchased shares of MRK during the specified class period are encouraged to register for the class action by April 14, 2025, to potentially become lead plaintiffs [4]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case [4]. Firm's Mission - The Gross Law Firm aims to protect investors' rights who have suffered losses due to deceit, fraud, and illegal business practices, ensuring companies adhere to responsible business practices [5].